Announcement
On Wednesday, 19 August 2026, CellBios, a biotechnology and life‑sciences leader headquartered in Chennai, issued a press release announcing plans to establish a major new advanced manufacturing facility in Dindigul, Tamil Nadu. The new site is intended to complement the company’s existing operations at Karapakkam, Chennai.
Facility Focus and Capabilities
The Dindigul plant will be dedicated to large‑scale manufacturing of single‑use products serving cell and gene therapy (CGT), bioprocessing, infusion and other medical applications. It will leverage modern technologies and rigorous quality systems to meet rising domestic and international demand for advanced healthcare solutions.
Employment and Regional Impact
The project is projected to create more than 100 direct jobs across skilled, technical and operational roles, thereby strengthening the regional industrial and supply‑chain ecosystem. CellBios highlights the initiative as a driver of localized high‑tech manufacturing and self‑reliance under the Aatmanirbhar Bharat programme, as well as a catalyst for the growth of Tamil Nadu’s medical‑device manufacturer ecosystem under the Vettri Tamizhnadu vision. The expansion also aims to foster advanced technology development, research integration, and workforce skill development in the region.
Commitment to Manufacturing Excellence
CellBios emphasizes that the new facility reinforces its long‑term commitment to expanding India’s research‑backed manufacturing capabilities. The added capacity is expected to help the company serve growing domestic healthcare needs and accelerate global exports of its products.
About CellBios
CellBios describes itself as a deep‑tech, innovation‑driven biotechnology company focused on transforming global healthcare through high‑precision solutions. Its portfolio includes single‑use solutions for blood component and bone‑marrow processing, upstream and downstream processing, biotech, cord‑blood processing, cell and gene therapy, tissue therapy, infusion and other critical medical applications. The company’s advanced manufacturing infrastructure features Class 10,000 clean rooms, ISO 13485 certification and operations aligned with stringent Good Manufacturing Practice (GMP) standards, enabling the delivery of sterile and non‑sterile products with consistent quality, precision and reliability.
Disclaimer: The above content is a press release. PTI takes no editorial responsibility for the same.